Document ID: chunk:federal_register_of_legislation:F2024L01389:schedule:1:p29
Version: federal_register_of_legislation:F2024L01389
Segment Type: schedule
Provision Reference: sch 1 (pt 29/66)
Character Range: 79816–83124

30 mg  Oral  Anamorph  RW  MP NP PDP  C10758                                     P10758                                     10  0                                             20
Morphine  Tablet containing morphine sulfate pentahydrate 30 mg  Oral  Anamorph  RW  PDP        C10859                                     P10859                                     20  0                                             20
Morphine  Tablet containing morphine sulfate pentahydrate 30 mg  Oral  Anamorph  RW  MP NP      C10764 C10770 C10775 C10777 C10837 C10891  P10764 P10770 P10775 P10777 P10837 P10891  20  0  V10764 V10770 V10775 V10777 V10837 V10891  20
Morphine  Tablet containing morphine sulfate pentahydrate 30 mg  Oral  Anamorph  RW  MP NP      C6168                                      P6168                                      20  2                                             20

[194] Schedule 1, Part 1, entries for Naloxone
substitute:
Naloxone  Injection containing naloxone hydrochloride 400 micrograms in 1 mL ampoule     Injection  Naloxone Hydrochloride (DBL)  PF  MP NP PDP        5  0     5
Naloxone  Injection containing naloxone hydrochloride 400 micrograms in 1 mL ampoule     Injection  Naloxone Juno                 JU  MP NP PDP        5  0     5
Naloxone  Injection containing naloxone hydrochloride 400 micrograms in 1 mL ampoule     Injection  NALOXONE SXP                  XN  MP NP PDP        5  0     5
Naloxone  Injection containing naloxone hydrochloride 2 mg in 2 mL pre-filled syringe    Injection  Prenoxad                      FF  MP NP PDP        1  0     1
Naloxone  Nasal spray 1.8 mg (as hydrochloride dihydrate) in 0.1 mL single dose unit, 2  Nasal      Nyxoid                        MF  MP NP PDP        1  0     1

[195] Schedule 1, Part 1, entries for Nifedipine in the form Tablet 30 mg (controlled release)
omit:
Nifedipine  Tablet 30 mg (controlled release)  Oral  Addos XR 30  RW  MP NP             30  5     30
Nifedipine  Tablet 30 mg (controlled release)  Oral  Addos XR 30  RW  MP NP     P14238  60  5     30

[196] Schedule 1, Part 1, entries for Nifedipine in the form Tablet 60 mg (controlled release)
omit:
Nifedipine  Tablet 60 mg (controlled release)  Oral  Addos XR 60  RW  MP NP             30  5     30
Nifedipine  Tablet 60 mg (controlled release)  Oral  Addos XR 60  RW  MP NP     P14238  60  5     30

[197] Schedule 1, Part 1, entry for Olanzapine in each of the forms: Powder for injection 210 mg (as pamoate monohydrate) with diluent; Powder for injection 300 mg (as pamoate monohydrate) with diluent; and Powder for injection 405 mg (as pamoate monohydrate) with diluent
omit from the column headed "Circumstances": C4304 substitute: C4246
[198] Schedule 1, Part 1, entries for Olanzapine in the form Tablet 2.5 mg
(a) insert in numerical order in the column headed "Circumstances" (all instances): C4246
(b) omit from the column headed "Circumstances" (all instances): C5856
[199] Schedule 1, Part 1, entries for Olanzapine in the form Tablet 5 mg
(a) insert in numerical order in the column headed "Circumstances" (all instances): C4246
(b) omit from the column headed "Circumstances" (all instances): C5856
[200] Schedule 1, Part 1, entries for Olanzapine in the form Tablet 5 mg (orally disintegrating)
(a) insert in numerical order in the